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a b s t r a c t
Histone lysine methyltransferases G9a and GLP are validated targets for the development of new epige-
netic drugs. Most, if not all, inhibitors of G9a and GLP target the histone substrate binding site or/and the
S-adenosylmethionine cosubstrate binding site. Here, we report an alternative approach for inhibiting the
methyltransferase activity of G9a and GLP. For proper folding and enzymatic activity, G9a and GLP con-
tain structural zinc fingers, one of them being adjacent to the S-adenosylmethionine binding site. Our
work demonstrates that targeting these labile zinc fingers with electrophilic small molecules results in
ejection of structural zinc ions, and consequently inhibition of the methyltransferase activity. Very effec-
tive Zn(II) ejection and inhibition of G9a and GLP was observed with clinically used ebselen, disulfiram
and cisplatin.
 2018 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Histone posttranslational modifications (PTMs), including
methylation, acetylation, phosphorylation and many others, play
an important role in human gene regulation.1 Methylation of lysine
residues is catalyzed by members of histone lysine methyltrans-
ferases (KMTs) that transfer the methyl group from S-adenosylme-
thionine (SAM) to lysine residues on histone N-terminal tails, core
histones and non-histone proteins. Recent structural, mutagenesis
and molecular modelling studies provided basic mechanistic
insight into histone methyltransferase catalysis.2–5 SET domain-
containing proteins G9a and its highly related homologue G9a-like
protein (GLP) (also known as EHMT2 and EHMT1, respectively) cat-
alyze mono-, di- and trimethylation of lysine 9 on histone 3
(H3K9me1/2/3, Fig. 1a) and several other proteins.6 The highest
methylation mark (H3K9me3) results in formation of heterochro-
matin, i.e. the transcriptionally inactive form of chromatin, and
has been linked to the development and maintenance of various
types of cancer.7 For instance, recent work has shown that
increased expression of G9a in aggressive lung cancer cells is asso-
ciated with greater mortality in patients.8 Therefore G9a and GLP
have been recognized as validated targets for development of small
molecule inhibitors for therapies against a variety of diseases,
including cancer.9
Recent medicinal chemistry studies have demonstrated
that inhibition of G9a and GLP (and other KMTs) can be achieved
by small molecules that act as histone-competitive or/and
SAM-competitive inhibitors.10–12 BIX-01294, the first known selec-
tive inhibitor of G9a, was reported in 2007.13 This small molecule
inhibitor, which was identified by high throughput screening, tar-
gets the histone binding site. Since its discovery, the structure of
BIX-01294 has been used in various structure-activity relationship
(SAR) explorations and structure-based design studies, which led
to the development of inhibitors with an improved potency and
selectivity, and reduced toxicity to cells, such as UNC0638,14 A-
366,15 E72,16 and DCG066.17 Few SAM-competitive inhibitors of
G9a and GLP have also been recently reported, including BIX-
01338 and BRD4770.13,18 However, SAM-competitive inhibitors
are often unselective due to high homology in SAM-binding sites
between different methyltransferases. Most known inhibitors have
similar inhibitory activity against G9a and GLP, and developing
selective inhibitors for either one is considered challenging due
to their high protein homology and similarity of the histone and
SAM binding sites (80%).19 Nonetheless, recent work has shown
that a high degree of selective inhibition can be achieved; MS012
and related structures have up to 140-fold selectivity for GLP over
G9a.20
In order to establish proper folding and enzymatic activity, G9a
and GLP methyltransferases each contain four structural zinc ions.
Both enzymes contain two distinguishable types of zinc fingers;
three Zn(II) ions are chelated in a triangular cluster by 9 cysteines
(Fig. 1b, top left), whereas one Zn(II) ion is chelated by 4 cysteines
in a Cys4-type zinc finger (Fig. 1b, top right).21 The latter zinc finger
is adjacent to the SAM-binding site. Recent studies have high-
lighted that significant efforts have been made in developing
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strategies for targeting labile Zn-fingers with electrophilic small
molecules, most notably by ebselen and disulfiram.22,23 Inhibition
of important biological processes by the release of structural zinc
ions has been shown for a variety of proteins, including nucleocap-
sid 7,24 p300,25 c-butyrobetaine,26 and histone lysine demethylase
JMJD2A.27 We hypothesized that it would be possible to inhibit
G9a and GLP methyltransferases by small molecule-mediated ejec-
tion of structural zinc ions. It was envisioned that the ejection of Zn
(II) from the Cys4-Zn finger, which is located adjacent to the SAM-
binding site (Fig. 1b, top right), would lead to a loss of the methyl-
transferase activity of G9a and GLP.
We initiated our investigations by testing whether 20 known
and potential zinc ejectors, including clinically used ebselen, disul-
firam and cisplatin, have an ability to inhibit the G9a and GLP
methyltransferase activity (Table 1). The chosen examples include:
selenium-based compounds 1–7, sulfur-based compounds 8–15,
and various other potential Zn(II) ejectors 16–20. Initially, all com-
pounds were tested at a concentration of 10 mM against both G9a
and GLP. Therefore, methylation of a synthetic 15-mer peptide
(residues 1–15) mimic of the N-terminal histone 3 tail containing
a lysine at position 9 (H3K9) was monitored using matrix assisted
laser desorption-ionization time-of-flight (MALDI-TOF) mass spec-
trometry.28 Representative inhibition data for GLP-catalyzed
methylation of H3K9 can be found in Fig. 2. Molecules that did
not show significant inhibition at 10 mM, were also tested at 100
mM. Inhibition data at 10 and 100 mM for all other compounds
can be found in Figs. S1–S4. For those compounds that showed
>50% inhibition at a concentration of 100 mM, half maximum inhi-
bitory concentrations (IC50) were obtained using a MALDI-TOF
based assay using 200 nM enzyme concentrations (Table 1 and
Figs. S1–S32).
In the absence of inhibitor, 15-mer H3K9 histone mimic under-
went near quantitative trimethylation (m/z = 1603.1 Da, Fig. 2a);
this result is consistent with our recent studies on KMT-catalyzed
methylation of lysine.29 For ebselen 1, which is known to inhibit
various zinc finger containing proteins, such as metallothionein,30
histone lysine demethylase JMJD2A,27 and c-butyrobetaine
hydroxylase,26 submicromolar IC50 values were obtained
(0.40 mM for G9a and 0.73 mM for GLP), demonstrating very effec-
tive inhibition. Notably, at 10 mM concentration of ebselen, only
unmethylated peptide was observed in MALDI-TOF spectrum
(Fig. 2b, m/z = 1560.9). Related seleno compounds 2–5 were also
observed to be excellent inhibitors of G9a and GLP; IC50 values
were found to be 0.45–4.4 mM for G9a, and 1.0–4.9 mM for GLP.
Sodium selenate 6 only showed 10% inhibition for G9a and GLP
at 100 mM concentration (Figs. S2 and S4). Diphenyl diselenide 7
inhibited G9a and GLP with IC50 = 0.55 lM and 0.86 lM,
respectively.
Having shown that selenium-based compounds act as good
inhibitors of G9a and GLP, we examined related sulfur-based small
molecules as potential inhibitors for these two methyltransferases.
Dithiocarbamates disulfiram 8 (Fig. 2c) and thiram 9 inhibited
the activity of G9a with submicromolar IC50 values of 0.60 and
a) 
b) 
Fig. 1. a) G9a- and GLP-catalyzed methylation of H3K9 (n = 1, 2, 3); b) Crystal
structure of GLP in complex with histone 3 peptide (yellow) and S-adenosylhomo-
cysteine (SAH, light cyan); a zoomed view on the Cys residues (magenta) involved
in the chelation of structural Zn(II) (orange) (PDB ID: 2RFI).
Table 1
Inhibition IC50 data.a
1: 0.40b; 0.73c µM 2: 0.45; 1.0 µM 3: 1.2; 1.1 µM
4 0.79; 1.5 µM 5: 4.4; 4.9 µM 6: >100 µM
7 0.55; 0.86 µM 8: 0.60; 1.6 µM 9: 0.55; 1.1 µM
10: 9.2; 81 µM 11: 0.65; 2.7 µM 12: 15; >100 µM
13: >100 µM 14: >100 µM
15: >100 µM 16: 0.50; 1.7 µM 17: 2.0;14 µM
18: 54; >100 µM 19: >100 µM 20: 1.4; 1.7 µM
aHalf maximum inhibitory concentration (IC50) obtained at 200 nM enzyme
concentration.
bIC50 for G9a.
cIC50 for GLP.
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0.55 mM, whereas for GLP the observed IC50 values are 1.6 and 1.1
mM, respectively. Inhibition by clinically safe disulfiram is particu-
larly important, as it has been used for decades for treatment alco-
holism by targeting acetaldehyde dehydrogenase (ADH), thereby
causing instantaneous nausea upon consumption of alcohol.31
Besides ADH, disulfiram is also known to inhibit hepatitis C viral
replication by targeting a labile zinc finger,32 and to induce apop-
tosis in a number of human cancer cell lines or inhibit cancer cell
growth.33–35 Sodium diethyldithiocarbamate 10, the reduced form
of disulfiram, was found to only poorly inhibit GLP. This result is
consistent with observations on inhibition of HIV-1 nucleocapsid
protein.36
2,20-Dithiodipyridine 11, also known as aldrithiol, is a known
zinc ejector, targeting for instance the zinc finger in nucleocapsid
protein of human immunodeficiency virus type 1.37 11 inhibited
G9a activity with IC50 = 0.65 mM and GLP with IC50 = 2.6 mM. We
also tested disulfide cysteamine dihydrochloride salt 12, but its
IC50 value was found to be above 100 mM for GLP, whereas for
G9a an IC50 value of 15 mM was obtained. Glutathione, in both
the reduced (13) and oxidized (14) form, did not inhibit G9a and
GLP. Also, no inhibition was observed for cystamine 15, the
reduced form of cysteamine dihydrochloride. Azidocarbonamide
16 showed very high inhibition activity against both G9a and
GLP (IC50 = 0.50 and 1.7 mM, respectively). Naphthoquinone 17
and ninhydrin 18, both known to eject zinc from p300,25 were also
tested against G9a and GLP. Naphthoquinone 17 was observed to
be a potent inhibitor of G9a with an IC50 value of 2.0 mM, whereas
it inhibited GLP with IC50 = 14 mM. Ninhydrin 18 only poorly inhib-
ited GLP (40% inhibition at 100 mM, Fig. S4) and an IC50 value of
54 mM was observed for G9a. In addition, anthraquinone 19, a
structurally related analogue of naphthoquinone, exhibited very
poor inhibition activity (20% for both G9a and GLP) at 100 mM.
Finally, inhibitory activity of cisplatin 20 was evaluated. Cisplatin
is a potent chemotherapeutic drug and is known to be highly reac-
tive towards Cys4 or Cys3His type Zn-fingers.38 Importantly, we
found that cisplatin inhibits G9a and GLP with similar IC50 values
of 1.4 and 1.7 mM respectively.
The observations that several Se- and S-based electrophiles,
including clinically used ebselen and disulfiram, possess excellent
inhibition activity against G9a and GLP prompted us to examine
their mode of action. We envisioned that they inhibit G9a and
GLP by the release of structural zinc ions, as a result of covalent
modification of cysteine residues. The release of zinc from G9a
and GLP was therefore monitored using the Zn2+-selective indica-
tor FluoZinTM-3. In line with observed MALDI-TOF data, we found
that zinc was released from both methyltransferases in the pres-
ence of those compounds that showed inhibitory activity
(Figs. S33–S39). Because of their current use in clinics, we were
particularly interested in inhibition of G9a/GLP by ebselen, disulfi-
ram and cisplatin. Therefore, zinc release from G9a and GLP in the
presence of various concentrations of ebselen, disulfiram and cis-
platin was monitored over time in the presence of FluoZin-3
(Fig. 3a–c). We observed that ebselen ejects Zn(II) very rapidly
(within minutes) for both G9a and GLP; disulfiram and cisplatin
also have the ability to eject zinc ions from G9a/GLP, but require
somewhat longer times to achieve it (Fig. 3b–c).
Based on a calibration curve with known Zn(II) concentrations,
a dose-response curve for the amount of zinc released from each
methyltransferase was plotted (GLP Fig. 3d–f, G9a Fig. S40). Each
methyltransferase contains in total four structural zinc ions, one
of which is very close to the active site, and three at a more distant
location (Fig. 1). In the presence of ebselen (>25 lM), all 4 zinc ions
were released from G9a and GLP, whereas higher concentrations of
disulfiram (>50 mM) were required for complete zinc ejection. On
average only 2.5 Zn(II) ions are removed after one hour in the
presence of 100 mM cisplatin, although it is possible that all four
zinc ions can be released after prolonged time, and/or at even
higher concentrations of cisplatin. We also tested whether
UNC0638,14 a very potent histone competitive inhibitor for G9a
and GLP, was able to eject structural Zn(II); as expected, no zinc
release was observed (Figs. S37 and S38).
Having shown that ebselen and disulfiram effectively inhibit
G9a and GLP via zinc ejection mechanism, we next explored
whether the folding of these two enzymes has been affected in
Fig. 2. Representative MALDI-TOF MS data of a) GLP-catalyzed methylation of H3K9 peptide (m/z = 1561.0); b) with 10 mM ebselen; c) with 10 mM disulfiram; d) with 10 mM
cisplatin.
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the presence ebselen and disulfiram. In order to investigate poten-
tial changes to the secondary and/or tertiary structure of these
methyltransferases, we employed circular dichroism (CD), a well-
established tool in protein/peptide research.39 Upon the addition
of 100 mM of ebselen or disulfiram to either 2 mM G9a or GLP, we
observed significant distortions in the CD spectrum (Figs. S40
and S41), implying that both enzymes became partially unfolded.
In conclusion, we have demonstrated that the ejection of struc-
tural zinc ions from G9a and GLP in the presence of selenium-, and
sulfur-containing electrophilic small molecules leads to inhibition
of these two biomedically important epigenetic enzymes. Our
work demonstrates that clinically used ebselen, disulfiram and cis-
platin act as very effective inhibitors of G9a and GLP with submi-
cromolar or low micromolar IC50 values. It is possible that the
observed physiological effects of these molecules may in part arise
as a result of their ability to affect epigenetic processes regulated
by G9a and GLP methyltransferases. Inhibition of biomedically
important epigenetic processes is currently a subject of intensive
investigations, therefore we envision that future studies will lead
to important advances in design and development of specific inhi-
bitors of the therapeutic potential. Although it is unlikely that
highly electrophilic compounds studied here, most notably ebse-
len,23 act as specific inhibitors of endogeneous proteins, it might
be possible that exploring a broader chemical space via substitu-
tions on the ebselen and disulfiram scaffolds may lead to a higher
degree of specificity for certain protein targets. Detailed structure-
activity relationships studies on small molecules that target struc-
tural zinc fingers may direct a design of novel type of inhibitors
with an improved selectivity. Towards this aim, our work high-
lights that targeting zinc finger sites of histone lysine methyltrans-
ferases is an alternative strategy to commonly used approaches
that target histone substrate and SAM cosubstrate binding sites;
this strategy leads to efficient inhibition of G9a and GLP histone
lysine methyltransferases that possess structural zinc ions.
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